Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | DGKA | P23743 | 1/20 | 1.00 |
| ▸ | DGKG | P49619 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | HTR1A | P08908 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MPO | P05164 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9788355 | 0.86 | MAPT (0.75) | MAPTHIF1ADGKADGKGHTR2A | |
| Hydrochloric Acid SCHEMBL9788298 | 0.85 | MAPT (0.74) | MAPTHIF1ADGKADGKGHTR2A | |
| Altanserin SCHEMBL404849 | 0.82 | HTR2A (1.00) | MAPTHIF1ADGKADGKGHTR2A | |
| Altanserin SCHEMBL12629110 | 0.82 | HTR2A (1.00) | MAPTHIF1ADGKADGKGHTR2A | |
| Altanserin SCHEMBL30136526 | 0.82 | HTR2A (1.00) | MAPTHIF1ADGKADGKGHTR2A | |
| Altanserin SCHEMBL30136524 | 0.82 | HTR2A (1.00) | MAPTHIF1ADGKADGKGHTR2A | |
| Altanserin SCHEMBL15662949 | 0.81 | HTR2A (1.00) | MAPTHIF1ADGKADGKGHTR2A | |
| SCHEMBL17978417 | 0.81 | MAPT (0.68) | MAPTHIF1ADGKADGKGHTR2A | |
| SCHEMBL2730275 | 0.79 | ALDH1A1 (1.00) | MAPTHIF1ADGKADGKGHTR2A | |
| Hydrochloric Acid SCHEMBL2730111 | 0.78 | ALDH1A1 (0.97) | MAPTHIF1ADGKADGKGHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022178986-A1 | METHOD AND DRUG FOR INDUCING DIFFERENTIATION OF STEM CELLS INTO MESODERM LINEAGE OR TROPHOBLAST LINEAGE | 澳门大学 | 2022-09-01 | — | — | WO | claimed |
| US-10010584-B2 | Treatment of depressive disorders | WEST VIRGINIA UNIVERSITY (US) | 2018-07-03 | — | — | US | claimed |
| US-20130165453-A1 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE | 2013-06-27 | — | — | US | claimed |
| US-20130165375-A1 | TREATMENT OF DEPRESSIVE DISORDERS | BLANCHETTE ROCKEFELLER NEUROSCIENCE INSTITUTE (US) | 2013-06-27 | — | — | US | claimed |
| US-20110288022-A1 | TREATMENT OF DEPRESSIVE DISORDERS | WEST VIRGINIA UNIVERSITY | 2011-11-24 | — | — | US | claimed |
| US-7803400-B2 | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2010-09-28 | — | — | US | claimed |
| CN-122012625-A | Viral vector production | 牛津生物医学（英国）有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | THE BROAD INSTITUTE, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4661869-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20250345491-A1 | IMPROVED NERVE REGENERATION SCAFFOLD FOR ACCELERATED REGROWTH | LINTEC OF AMERICA, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| CN-120904154-A | Preparation method of diacylglycerol kinase inhibitor | 苏州亚科科技股份有限公司 | 2025-11-07 | — | — | CN | disclosed |
| US-20080003181-A1 | Treatment of depressive disorders | WEST VIRGINIA UNIVERSITY | 2008-01-03 | — | — | US | disclosed |
| US-20080004332-A1 | Methods for alzheimer's disease treatment and cognitive enhancement | ALKON DANIEL L | 2008-01-03 | — | — | US | disclosed |
| WO-2007002285-A2 | METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20050266510-A1 | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-01 | — | — | US | disclosed |
| EP-1409679-A2 | NOV-X PROTEINS AND NUCLEIC ACIDS ENCODING SAME | Curagen Corporation (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002068652-A9 | NOV-X PROTEINS AND NUCLEIC ACIDS ENCODING SAME | CURAGEN CORP (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002068652-A2 | NOV-X PROTEINS AND NUCLEIC ACIDS ENCODING SAME | CURAGEN CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165453-A1 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | BDNF, NGF, NTRK2 | MAPT 1910/4885HIF1A 2787/4885DGKA 34/4885 |
| US-20110288022-A1 | TREATMENT OF DEPRESSIVE DISORDERS | FGF1, FGFR1, FGFR3 | MAPT 2333/4885HIF1A 74/4885DGKA 664/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | MAPT 4812/4885HIF1A 4254/4885DGKA 3/4885 |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | GPR3, GALR3, NR4A3 | MAPT 4798/4885HIF1A 1172/4885DGKA 2268/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | MAPT 1780/4885HIF1A 1940/4885DGKA 4723/4885 |
| US-20080004332-A1 | Methods for alzheimer's disease treatment and cognitive enhancement | BACE1, PRKCH, GSAP | MAPT 446/4885HIF1A 3632/4885DGKA 43/4885 |
| US-20130165375-A1 | TREATMENT OF DEPRESSIVE DISORDERS | FGF1, FGFR1, FGFR3 | MAPT 2302/4885HIF1A 73/4885DGKA 685/4885 |
| US-20080003181-A1 | Treatment of depressive disorders | FGF1, FGFR1, FGFR3 | MAPT 2333/4885HIF1A 74/4885DGKA 664/4885 |
| US-10010584-B2 | Treatment of depressive disorders | FGF1, FGFR1, FGFR3 | MAPT 2302/4885HIF1A 73/4885DGKA 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.